Sustained disease-activity-free status in patients with relapsing-remitting multiple sclerosis treated with cladribine tablets in the CLARITY study: a post-hoc and subgroup analysis
Sustained disease-activity-free status in patients with relapsing-remitting multiple sclerosis treated with cladribine tablets in the CLARITY study: a post-hoc and subgroup analysis
Abstract
BACKGROUND: On the basis of various clinical and MRI measurements, the phase 3 Cladribine Tablets Treating Multiple Sclerosis Orally (CLARITY) study in patients with relapsing-remitting multiple sclerosis (RRMS) showed that short-course oral treatment with cladribine at cumulative doses of 3·5 and 5·25 mg/kg over 96 weeks was more effective than placebo. Achieving sustained freedom from disease activity is becoming a viable treatment goal in RRMS; we therefore aimed to assess the effects ofcladribine on this composite outcome measure by doing a post-hoc analysis of data from the CLARITY study... Read More - http://www.msrc.co.uk/index.cfm/fuseact ... ageid/1629
Disease-activity-free status in patients with cladribine
Disease-activity-free status in patients with cladribine
MS-UK - http://www.ms-uk.org/
-
- Similar Topics
- Replies
- Views
- Last post
-
- 0 Replies
- 153 Views
-
Last post by NHE
-
- 0 Replies
- 1763 Views
-
Last post by jimmylegs
-
- 0 Replies
- 1214 Views
-
Last post by frodo
-
- 0 Replies
- 1029 Views
-
Last post by frodo
-
- 3 Replies
- 1560 Views
-
Last post by jimmylegs
-
- 0 Replies
- 1085 Views
-
Last post by NHE
-
- 1 Replies
- 1568 Views
-
Last post by ElliotB
-
- 0 Replies
- 1730 Views
-
Last post by maggieMSOC
-
- 0 Replies
- 1612 Views
-
Last post by NHE